Thrombosis research最新文献

{"title":"Thrombectomy in high-risk pulmonary embolism – device versus thrombolysis: rationale and design of the TORPEDO-NL investigator-initiated, academically-sponsored, multicenter, open-label randomized controlled trial","authors":"W.J.E. Stenger ,&nbsp;C.A. den Uil ,&nbsp;W.J.R. Rietdijk ,&nbsp;I. Al Amri ,&nbsp;J.M. Montero-Cabezas ,&nbsp;C.V. Elzo Kraemer ,&nbsp;T.E. van Mens ,&nbsp;C.L. Meuwese ,&nbsp;N.M.D.A. van Mieghem ,&nbsp;M.N. Lauw ,&nbsp;L.M. van den Toorn ,&nbsp;S. Levolger ,&nbsp;K.M. van de Luijtgaarden ,&nbsp;R.A. Sprenger ,&nbsp;J.M. van Dongen ,&nbsp;F. Imani ,&nbsp;M. Meuwissen ,&nbsp;K.M. Kant ,&nbsp;R.A.H.M. Aarts ,&nbsp;K. Winckers ,&nbsp;J. Jongkind","doi":"10.1016/j.thromres.2025.109420","DOIUrl":"10.1016/j.thromres.2025.109420","url":null,"abstract":"<div><h3>Background</h3><div>Catheter-directed thrombectomy (CDT) is a promising alternative to full dose thrombolysis in patients with acute high-risk pulmonary embolism (PE), expected to have a more direct effect on pulmonary artery clot burden and a better safety profile. Randomized trials evaluating the safety and efficacy of CDT in high-risk patients are currently unavailable.</div></div><div><h3>Methods and results</h3><div>The TORPEDO-NL study is an investigator-initiated, publicly-funded, multicenter, open-label randomized controlled trial designed to evaluate the superiority of CDT over systemic thrombolysis in patients with high-risk PE. Adults with: 1) confirmed acute PE, 2) a high risk for mortality, and 3) CDT available and technically feasible, will be randomized 2:1 to CDT versus systemic thrombolysis. The primary outcome is the composite incidence of all-cause mortality, treatment failure, major bleeding, and all-cause stroke at day 30. Secondary outcomes include desirability of outcome ranking (DOOR) at day 7, length of hospital stay, patient-reported outcomes including quality of life and symptom burden, functional recovery, and 1-year cost-effectiveness. The trial anticipates recruiting 111 patients and is funded by the The Netherlands Health Care Institute, The Netherlands Organization for Health Research and Development, the Dutch Heart Foundation, and unrestricted grants from Penumbra Inc. and Inari Medical. <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> number, <span><span>NCT06833827</span><svg><path></path></svg></span>.</div></div><div><h3>Conclusions</h3><div>TORPEDO-NL is the first publicly-funded randomized trial to investigate the effect of CDT treatment specifically in high-risk PE patients. The trial is anticipated to play an important role in revising recommendations for high-risk PE treatment in international guidelines.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"255 ","pages":"Article 109420"},"PeriodicalIF":3.4,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145201345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of thrombocytopenia in patients with cancer-associated isolated distal deep vein thrombosis treated with edoxaban for 12 months versus 3 months: Insights from the ONCO DVT study","authors":"Yutaro Miyoshi ,&nbsp;Yugo Yamashita ,&nbsp;Takeshi Morimoto ,&nbsp;Nao Muraoka ,&nbsp;Michihisa Umetsu ,&nbsp;Yuji Nishimoto ,&nbsp;Takuma Takada ,&nbsp;Yoshito Ogihara ,&nbsp;Tatsuya Nishikawa ,&nbsp;Nobutaka Ikeda ,&nbsp;Kazunori Otsui ,&nbsp;Daisuke Sueta ,&nbsp;Yukari Tsubata ,&nbsp;Masaaki Shoji ,&nbsp;Ayumi Shikama ,&nbsp;Yutaka Hosoi ,&nbsp;Yasuhiro Tanabe ,&nbsp;Ryuki Chatani ,&nbsp;Kengo Tsukahara ,&nbsp;Naohiko Nakanishi ,&nbsp;Takeshi Kimura","doi":"10.1016/j.thromres.2025.109419","DOIUrl":"10.1016/j.thromres.2025.109419","url":null,"abstract":"","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"253 ","pages":"Article 109419"},"PeriodicalIF":3.4,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144830892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A real-world pharmacovigilance analysis of the FDA adverse event reporting system database for emicizumab","authors":"Tianyi Li ,&nbsp;Dongping Huang ,&nbsp;Yizhi Jiang","doi":"10.1016/j.thromres.2025.109422","DOIUrl":"10.1016/j.thromres.2025.109422","url":null,"abstract":"<div><h3>Background and objectives</h3><div>Emicizumab has fundamentally changed the clinical management of hemophilia A. Despite its benefits, concerns about adverse events (AEs) have risen. This retrospective study used disproportionality analysis of FAERS data from 2017 to 2023 to examine AEs associated with emicizumab, either alone or in combination with activated prothrombin complex concentrate (aPCC) or recombinant activated factor VII (rFVIIa), as well as the timing of these AEs.</div></div><div><h3>Methods</h3><div>Established algorithms (ROR, PRR, BCPNN, and MGPS) were used to assess correlations and calibrated <em>p</em>-values.</div></div><div><h3>Results</h3><div>Based on 1198 AEs, we identified 126 cases that met four algorithmic criteria. AEs associated with emicizumab included primarily joint pain and injection site reactions (ISRs), consistent with the drug label. Additionally, we observed thrombotic events related to emicizumab's black box warning. Specifically, we found that emicizumab poses increased risks of thrombosis when used in conjunction with aPCC or rFVIIa to treat breakthrough bleeds. After excluding reports related to the progression of hemophilia, we obtained 850 AEs with reported onset times. The median onset time for AEs was 106 days, with 46.59 % occurring within the first 90 days of emicizumab treatment.</div></div><div><h3>Conclusion</h3><div>Our study demonstrates the importance of early monitoring and interventions to minimize AEs and alleviate patient suffering.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"254 ","pages":"Article 109422"},"PeriodicalIF":3.4,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144863949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between the PROTECHT score and mortality in patients with cancer: results from a prospective cohort study","authors":"Yara Abrão Vasconcelos Vivas ,&nbsp;Ester Martins Camillozzi Medina ,&nbsp;Eliabe Silva de Abreu ,&nbsp;Dário Alves da Silva Costa ,&nbsp;Suely Meireles Rezende ,&nbsp;Daniel Dias Ribeiro","doi":"10.1016/j.thromres.2025.109421","DOIUrl":"10.1016/j.thromres.2025.109421","url":null,"abstract":"","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"253 ","pages":"Article 109421"},"PeriodicalIF":3.4,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144779370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Iron deficiency anemia as a risk factor associated with stroke and cerebral venous thrombosis in children and adults - a systematic review","authors":"Mai Erritzøe-Jervild ,&nbsp;Christina Kruuse ,&nbsp;Arkadiusz Weglewski ,&nbsp;Nina Vindegaard Sørensen","doi":"10.1016/j.thromres.2025.109425","DOIUrl":"10.1016/j.thromres.2025.109425","url":null,"abstract":"<div><h3>Objectives</h3><div>Iron deficiency anemia (IDA) might have an association with stroke and cerebral venous thrombosis (CVT), but no systematic evaluation of the literature has been conducted to support this. The aim of this systematic review was to assess IDA as a potential risk factor for stroke and CVT by analyzing all papers published on IDA-related strokes and CVTs.</div></div><div><h3>Methods and materials</h3><div>A systematic review by use of the databases EMBASE and Pubmed. The study was registered at PROSPERO before data collection and PRISMA guidelines were followed. Case reports and studies on IDA as a risk factor for stroke and CVT were included with no limitations, though papers not written in English were excluded.</div></div><div><h3>Results</h3><div>In total, 2202 papers were identified of which 87 were included, hereof 71 case reports or -series, 16 observational studies, and two papers comprising both categories. The 18 observational studies indicated an association of IDA with stroke, however, were limited by sample size. The case reports included 52 adult and 53 pediatric cases. Females accounted for 65.7 % of all reported cases. The median age of all included cases was 17.0 years (range 0.4–70.0). Mean hemoglobin was 6.7 g/dL (SD 2.3), and mean ferritin was 7 ng/mL (SD 6).</div></div><div><h3>Conclusion</h3><div>IDA is an under-investigated potential risk factor for stroke and CVT—especially in children and younger adults. Large-scale, longitudinal studies are needed to confirm IDA as a stroke and CVT risk factor and identify specific subgroups at a higher risk of stroke and CVT associated with IDA.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"253 ","pages":"Article 109425"},"PeriodicalIF":3.4,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144852583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is primary hemostasis involved in bleeding diathesis in patients with type 1 glycogen storage disease?","authors":"Floriane Devaux ,&nbsp;Claire Auditeau ,&nbsp;Cécile Bally ,&nbsp;Tiffany Pascreau ,&nbsp;Anais Brassier ,&nbsp;Myriam Dao ,&nbsp;Jean Baptiste Arnoux ,&nbsp;Oliver Wong ,&nbsp;Dominique Lasne ,&nbsp;Pascale de Lonlay ,&nbsp;Annie Harroche ,&nbsp;Delphine Borgel","doi":"10.1016/j.thromres.2025.109424","DOIUrl":"10.1016/j.thromres.2025.109424","url":null,"abstract":"<div><h3>Objectives</h3><div>Glycogen storage disease type I (GSD-I) is a metabolic disease associated with a bleeding tendency. Although decreased von Willebrand factor (VWF) and/or impaired platelet function have been reported in this condition, no direct link with bleeding has been demonstrated. The aim of this retrospective study was to assess the correlation between primary hemostasis abnormalities and haemorrhagic diathesis in a cohort of 19 GSD-I patients.</div></div><div><h3>Methods</h3><div>A Standardized International Society of Thrombosis and Hemostasis Bleeding Assessment Tool (ISTH-BAT) score was calculated for all patients to assess their bleeding history. Primary hemostasis was investigated by platelet closure time, VWF activity and antigen levels, and platelet aggregation.</div></div><div><h3>Results</h3><div>Seven of the 19 patients (37 %) had a positive ISTH-BAT score for age. Bleeding symptoms were essentially mucocutaneous. Thirteen patients (76 %) had a prolonged closure time with no significant difference whether ISTH-BAT was positive (ISTH-BATpos group) or negative (ISTH-BATneg group) (<em>p</em> = 0.60). Two patients in the ISTH-BATpos group had a moderate decrease in VWF levels. However, no statistical difference was observed between ISTH-BATpos and ISTH-BATneg groups regarding VWF activity (<em>p</em> = 0.40) or antigen (<em>p</em> = 0.82) levels either. Four patients had defective platelet aggregation, mainly in response to ADP agonist, with no significant difference between the two groups (<em>p</em> = 0.12).</div></div><div><h3>Conclusion</h3><div>As expected, GSD-I was found to be associated with an increased risk of mucocutaneous haemorrhage. However, no correlation was observed between primary hemostasis impairment and bleeding tendency in the present study.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"253 ","pages":"Article 109424"},"PeriodicalIF":3.4,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144842868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erythrocyte rheology is altered in haemophilia patients with advanced arthropathy. A case-control study","authors":"Fabian Tomschi ,&nbsp;Marijke Grau ,&nbsp;Wilhelm Bloch ,&nbsp;Thomas Hilberg","doi":"10.1016/j.thromres.2025.109423","DOIUrl":"10.1016/j.thromres.2025.109423","url":null,"abstract":"<div><h3>Background</h3><div>Haemophilia goes along with a lack of clotting factors, which can lead to bleedings mostly being of intraarticular nature. These patients (PwH) suffer from health implications attributed to the resulting haemophilc arthropathy. Even though the haemostatic system is widely studied in PwH, little is known about red blood cell (RBC) rheology. This study aims to explore RBC rheology focussing on deformability and aggregation in PwH and to describe potential influencing factors.</div></div><div><h3>Methods</h3><div>27 PwH and 27 healthy controls (HC) were included in this study. RBC deformability (EI_max, SS½, SS½/EI_max ratio) and aggregation (AI, Shear stress at disc min) were measured using ektacytometry and obtained from syllectograms. Haematological parameters were determined. The Haemophilia Joint Health Score (HJHS) was assessed indicating musculoskeletal impairment. Pain and pain sensitivity were measured using numeric rating scales and pressure algometry. Subjective physical functioning was assessed via questionnaires.</div></div><div><h3>Results</h3><div>PwH possess higher HJHS scores than HC (<em>p</em> &lt; .001) with a range of 11–69 points. All RBC deformability parameters (<em>p</em> ≤ .007) and Shear stress at disc min (<em>p</em> &lt; .001) are impaired in PwH compared to HC. Regarding haematological parameters, only red cell distribution width (<em>p</em> = .049) and haemoglobin (<em>p</em> = .024) were different. PwH reveal higher pain states (<em>p</em> ≤ .002) and lower physical functioning (<em>p</em> &lt; .001).</div></div><div><h3>Conclusions</h3><div>This study is the first to investigate RBC rheology in PwH with haemophilic arthropathy and shows that RBC rheological properties, particularly deformability, are impaired in this population. These observations might be attributed to advanced joint restrictions and higher pain states in PwH resulting in lower physical activity as well as to present co-morbidities and co-medication.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"253 ","pages":"Article 109423"},"PeriodicalIF":3.4,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144779369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anticoagulation therapy for patients with atrial fibrillation at primary care facilities in Beijing, China, 2017–2022","authors":"Mengyuan Fu ,&nbsp;Kexin Ling ,&nbsp;Zhiwen Gong ,&nbsp;Shujie Dong ,&nbsp;Huangqianyu Li ,&nbsp;Fang Wang ,&nbsp;Yang Xu ,&nbsp;Luwen Shi ,&nbsp;Joseph S. Ross ,&nbsp;Xiaodong Guan","doi":"10.1016/j.thromres.2025.109417","DOIUrl":"10.1016/j.thromres.2025.109417","url":null,"abstract":"","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"253 ","pages":"Article 109417"},"PeriodicalIF":3.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144757088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Quantitative protein mass spectrometry for multiplex measurement of coagulation and fibrinolytic proteins towards clinical application: What, why and how?”, [Thromb. Res. 241 (2024) 109090]","authors":"Eleonora Camilleri ,&nbsp;Mirjam Kruijt ,&nbsp;Paul L. den Exter ,&nbsp;Suzanne C. Cannegieter ,&nbsp;Nienke van Rein ,&nbsp;Yassene Mohammed ,&nbsp;Frits R. Rosendaal ,&nbsp;Christa M. Cobbaert ,&nbsp;Bart J.M. van Vlijmen ,&nbsp;L. Renee Ruhaak","doi":"10.1016/j.thromres.2025.109416","DOIUrl":"10.1016/j.thromres.2025.109416","url":null,"abstract":"","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"253 ","pages":"Article 109416"},"PeriodicalIF":3.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144749392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of direct oral anticoagulants compared to no anticoagulation for stroke prevention in atrial fibrillation patients with prior intracranial hemorrhage: A systematic review and meta-analysis","authors":"Muhammad Ibrahim ,&nbsp;Hassan Abdullah ,&nbsp;Aroosa Zafar ,&nbsp;Akash Kumar ,&nbsp;Fatima Ajmal ,&nbsp;Daniyal Talib ,&nbsp;Hamza Shabbir ,&nbsp;Mahnoor Shah ,&nbsp;Malaika Sardar ,&nbsp;Sarmad Masaud ,&nbsp;Mehrosh Zafar ,&nbsp;Zoya Habib ,&nbsp;F.N.U. Sagar ,&nbsp;Fatima Zahra","doi":"10.1016/j.thromres.2025.109418","DOIUrl":"10.1016/j.thromres.2025.109418","url":null,"abstract":"","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"253 ","pages":"Article 109418"},"PeriodicalIF":3.4,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144757313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}